Evaluation of the effect of erythropoetin mouthwash in mucositis

Evaluation of the effect of erythropoetin mouthwash in preventing the incidence and decreasing severity of mucositis in patients undergoing autologous bone marrow transplantation

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2015042518842N8

Enrollment

Registered

2015-05-03

Start date

2014-02-20

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: multiple myeloma. Condition 2: Non-Hodgkin lymphoma. Condition 3: Hodgkin lymphoma. multiple myeloma Non-Hodgkin lymphoma, unspecified Hodgkin lymphoma, unspecified

Interventions

Intervention 1: erythropoietin mouthwash (50 IU/mL, 15 ml four times a day from starting day of preparing chemotherapy until day +14 after transplantation. Intervention 2: pelacebo mouthwash (50 IU/mL

Prevention

Placebo

erythropoietin mouthwash (50 IU/mL, 15 ml four times a day from starting day of preparing chemotherapy until day +14 after transplantation

pelacebo mouthwash (50 IU/mL, 15 ml four times a day from starting day of preparing chemotherapy until day +14 after transplantation

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: inclusion criteria: age of at least 18 years old; patients with NHL, HD or MM receiving conditioning chemotherapy before autologousHSCT; signing written informed consent. exclusion criteria: Karnofsky performance status <70% or participation in another study; using an unlicensed product.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Incidence, severity and duration of oral mucositis. Timepoint: The starting day of preparing chemotherapy until day +21 after transplantation. Method of measurement: Daily oral examination based on the WHO criteria for grading mucositis.	—

Secondary

Measure	Time frame
Neutrophil and platelet engraftment. Timepoint: The starting day of preparing chemotherapy until day +21 after transplantation. Method of measurement: CBC test.;Duration of neutropenia. Timepoint: The starting day of preparing chemotherapy until day +21 after transplantation. Method of measurement: CBC test.;Duration of fever due to neutropenia. Timepoint: The starting day of preparing chemotherapy until day +21 after transplantation. Method of measurement: Temperatures measured under the tongue.;Duration of hospitalization. Timepoint: Discharge Time. Method of measurement: The number of hospitalization days.	—

Measure

Time frame

Neutrophil and platelet engraftment. Timepoint: The starting day of preparing chemotherapy until day +21 after transplantation. Method of measurement: CBC test.;Duration of neutropenia. Timepoint: The starting day of preparing chemotherapy until day +21 after transplantation. Method of measurement: CBC test.;Duration of fever due to neutropenia. Timepoint: The starting day of preparing chemotherapy until day +21 after transplantation. Method of measurement: Temperatures measured under the tongue.;Duration of hospitalization. Timepoint: Discharge Time. Method of measurement: The number of hospitalization days.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHesamodin Hosseinjani

School of Pharmacy, Tehran University of Medical Sciences

hosseinjanih@yahoo.com+98 21 6643 5807

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026